Acusphere SEC Filings

Type
Report
Date
CT ORDERCT ORDER-Formular1/10/2017
DD-Formular2/22/2012
D/AD/A-Formular7/7/2011
DD-Formular7/16/2010
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/30/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/26/2008
4Insidertransaktion6/9/2008
4Insidertransaktion6/9/2008
4Insidertransaktion6/9/2008
4Insidertransaktion6/9/2008
4Insidertransaktion6/9/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/6/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/30/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/20/2008
10-QQuartalsbericht5/8/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/8/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/29/2008
DEF 14ADEF 14A-Formular4/28/2008
PRE 14APRE 14A-Formular4/17/2008
4Insidertransaktion4/3/2008
4Insidertransaktion4/3/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/1/2008
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/7/2007
4Insidertransaktion11/16/2007
10-QQuartalsbericht11/8/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/8/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/5/2007
33-Formular10/5/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/5/2007
4Insidertransaktion10/3/2007
4Insidertransaktion10/3/2007
4Insidertransaktion9/6/2007
10-QQuartalsbericht8/8/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/8/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/6/2007
SC 13GSC 13G-Formular7/26/2007
S-8S-8-Formular7/25/2007
SC 13GSC 13G-Formular7/13/2007
4Insidertransaktion7/5/2007
4Insidertransaktion7/5/2007
4Insidertransaktion7/5/2007
SC 13GSC 13G-Formular7/3/2007
33-Formular7/2/2007
4Insidertransaktion6/28/2007
4Insidertransaktion6/28/2007
4Insidertransaktion6/28/2007
4Insidertransaktion6/28/2007
4Insidertransaktion6/28/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/22/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/15/2007
SC 13GSC 13G-Formular6/15/2007
424B5424B5-Formular6/12/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/12/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/21/2007
4Insidertransaktion5/17/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/11/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/11/2007
10-QQuartalsbericht5/10/2007
4Insidertransaktion5/10/2007
SC 13GSC 13G-Formular5/10/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/3/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/1/2007
DEF 14ADEF 14A-Formular4/30/2007
SC 13GSC 13G-Formular4/27/2007
SC 13GSC 13G-Formular4/13/2007
4Insidertransaktion4/4/2007
4Insidertransaktion4/4/2007
4Insidertransaktion4/4/2007
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/30/2006
SC 13G/ABeneficial ownership report2/14/2006
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/7/2006
4Insidertransaktion6/20/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/18/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/4/2005
4Insidertransaktion3/28/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/25/2005
4Insidertransaktion3/24/2005
4Insidertransaktion3/23/2005
4Insidertransaktion3/22/2005
4Insidertransaktion3/18/2005
4Insidertransaktion3/17/2005
4Insidertransaktion3/16/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/16/2005
4Insidertransaktion3/15/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/15/2005
4Insidertransaktion3/15/2005
10-KJahresbericht3/15/2005
4Insidertransaktion3/14/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/14/2005
4Insidertransaktion3/11/2005
4Insidertransaktion3/10/2005
4Insidertransaktion3/3/2005
4Insidertransaktion3/3/2005
SC 13GSC 13G-Formular3/3/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/2/2005
SC 13GSC 13G-Formular2/28/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/28/2005
424B2424B2-Formular2/18/2005
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/18/2005
424B5424B5-Formular2/18/2005

Acusphere Documents 2026

This page contains all official documents and SEC filings for Acusphere stock (ACUS, ISIN: US00511R8549). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Acusphere's regulatory filings.

Acusphere Stock analysis

Acusphere Acusphere Inc is a US-American company that was founded in 1993. It specializes in the development and marketing of advanced pharmaceuticals and therapeutic platforms in the fields of cardiology and pulmonology. The company is based in Lexington, Massachusetts and currently employs about 30 employees. The history of Acusphere goes back to the discovery of a new class of pharmaceutical agents, called microspheres. These spherical particles have a diameter of only a few micrometers and can have the ability to bind various therapeutic agents and release them in a targeted manner in the body. Acusphere has developed several innovative products and technologies based on these microspheres in recent years. One focus of the company is the development of therapies for patients with cardiovascular diseases such as heart failure or coronary artery disease. Another research area of ​​the company is the development of therapies for patients with lung diseases such as COPD or asthma. The business model of Acusphere is mainly based on the discovery and marketing of new drugs and therapies. In order to achieve these goals, the company works closely with leading scientific institutions and invests a significant portion of its budget in research and development. Acusphere is divided into several business areas, each of which includes different products and technologies. One of the most important business areas is the development of drugs for the treatment of cardiovascular diseases. An example of this is the drug EchoSphere, which was developed based on microspheres and is able to improve the oxygen supply to the heart muscle. Another important business area of ​​Acusphere is the development of products for the treatment of lung diseases such as COPD and asthma. For this purpose, the company has developed several new technologies that allow targeted delivery of medication to the lungs and its effects there. One of these technologies is the so-called Solutol technology, which allows medication to be concentrated in the alveoli of the lungs while avoiding unwanted side effects. In recent years, Acusphere has developed a number of innovative products and technologies that have great market potential due to their high efficacy and tolerability. The company is making every effort to bring these products to the market as quickly as possible and make a significant contribution to improving healthcare.